Related Experiment Video
Updated: Jun 3, 2026
Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing
Wei Zhao1,2,3, Qing Zhong1,2, Bao-Long Li1,4
1Department of Gastric Surgery, Fujian Medical University Union Hospital, No.29 Xin-quan Road, Fuzhou, Fujian Province, 350001, China.
Background:
Gastric cancer (GC) progression involves changes in immune responses, inflammation, and coagulation. The prognostic value of related biomarkers remains unclear. This study aimed to develop a novel immune-inflammation-fibrinogen score (FSL score) to predict outcomes in GC patients after radical gastrectomy.
Methods:
Clinicopathological data from 401 GC patients enrolled in a randomized controlled trial (2015-2016; ClinicalTrials.gov: NCT02327481) were retrospectively analyzed as the training cohort, with 173 patients included for external validation. Cox regression was used to construct the FSL score based on preoperative hematological markers and to evaluate its association with overall survival (OS) and recurrence-free survival (RFS). A nomogram incorporating the FSL score and clinicopathological factors was developed and evaluated using the C-index, time-dependent AUC, calibration curves, AIC, BIC, and decision curve analysis (DCA), and compared with the AJCC 8th TNM staging system.
Results:
Patients with high FSL scores had significantly better 3-year OS (training cohort: 87.4% vs. 71.3%, p = 0.001; validation cohort: 68.4% vs. 42.6%, p = 0.009) and RFS (training cohort: 81.0% vs. 67.6%, p = 0.001; validation cohort: 72.4% vs. 54.9%, p = 0.025). The FSL score independently predicted OS and RFS (all p < 0.05). A nomogram integrating the FSL score, preoperative CEA level, pT stage, pN stage, and postoperative chemotherapy outperformed the TNM system for OS (C-index: 0.806 vs. 0.757; AIC: 1378.25 vs. 1395.73; BIC: 1390.49 vs. 1394.10) and RFS (C-index: 0.803 vs. 0.763; AIC: 1310.10 vs. 1319.08; BIC: 1320.11 vs. 1322.26), with good discrimination, calibration, and clinical utility confirmed by DCA and external validation.
Conclusions:
The FSL score is a promising prognostic biomarker for GC patients undergoing radical gastrectomy. The proposed nomogram enables accurate and individualized survival prediction.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...